01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. A prospective observational multicenter study of balloon angioplasty for the treatment of native and recurrent coarctation of the aorta

Kevin C. Harris MD1, Wei Du PHD2, Collin G. Cowley MD3, Thomas J. Forbes MD2, Dennis W. Kim MD, PHD4,* andOn Behalf of the Congenital Cardiac Intervention Study Consortium (CCISC)

Objectives: Balloon angioplasty (BA) is an important treatment option for coarctation of the aorta. The congenital cardiovascular interventional study consortium (CCISC) represents a multi-institutional and multi-national effort to prospectively investigate congenital cardiac interventions. A prospective observational analysis of the efficacy and safety of balloon aortic angioplasty was conducted.

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Outcomes associated with balloon angioplasty for recurrent coarctation in neonatal univentricular and biventricular norwood-type aortic arch reconstructions

Wendy Whiteside MD1,*, Jennifer Hirsch-Romano MD, MS2, Sunkyung Yu MS1, Sara K. Pasquali MD, MHS1 andAimee Armstrong MD1

Objectives: We evaluated the use of, and outcomes associated with, balloon angioplasty (BA) for recurrent coarctation in single ventricle (SV) and two ventricle (2V) patients following a Norwood-type aortic arch reconstruction (NTAR).

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Initial clinical experience with the Coherex FlatStent™ and FlatStent™ EF PFO closure system for in-tunnel PFO closure: Results of the Coherex-EU study

Horst Sievert MD, FSCAI, FESC, FACC1,2,3,4,5,*, Nina Wunderlich MD3,4, Isabel Reiffenstein3,4, Peter Ruygrok MD, BSC, MBCHB, FRACP, FCSANZ, FESC6,7,8,9, Eberhard Grube MD, FSCAI, FACC10,11,12,13, Lutz Buellesfeld MD14, Bernhard Meier MD, FACC, FESC14, Joachim Schofer MD15, David Muller MBBS, MD, FRACP, FACC16, Randall K. Jones MD17 andLinda Gillam MD, FACC, FESC18

Objective: The Coherex-EU Study evaluated the safety and efficacy of PFO closure utilizing novel in-tunnel PFO closure devices.

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. Results of percutaneous closure of patent foramen ovale with the GORE® septal occluder

Meike Knerr, Stefan Bertog MD, Laura Vaskelyte, Ilona Hofmann MD andHorst Sievert MD*

Objective: The aim of this study was to evaluate the safety and efficacy of the GORE® Septal Occluder (GSO) at 1-, 6-, and 12-month follow-up in patients with a clinical indication for patent foramen ovale (PFO) closure.

01 junio 2014

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. The impact of regulatory approval and Medicare coverage on outcomes of carotid stenting

William A. Gray MD1,* andPatrick Verta MS Stat, DVM, MD2

Background: Carotid artery stenting (CAS) was introduced in the United States nearly a decade ago as a novel treatment of severe carotid stenosis. Voluminous and high-quality prospective data permit analysis of longitudinal trends in CAS outcomes.

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Coronary and Microvascular Physiology During Intra-Aortic Balloon Counterpulsation

Kalpa De Silva, MBBS, PhD∗; Matthew Lumley, MBBS, BSc∗; Balrik Kailey, BSc∗; Jordi Alastruey, PhD†; Antoine Guilcher, PhD‡; Kaleab N. Asrress, MA, BM, BCh∗; Sven Plein, MD, PhD†; Michael Marber, PhD∗; Simon Redwood, MBBS, MD∗; Divaka Perera, MA, MD∗

Objectives: This study sought to identify the effect of coronary autoregulation on myocardial perfusion during intra-aortic balloon pump (IABP) therapy.

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. The Relationship Between Post-Stent Strut Apposition and Follow-Up Strut Coverage Assessed by a Contour Plot Optical Coherence Tomography Analysis

Jung-Sun Kim, MD∗; Jinyong Ha, PhD†; Byeong-Keuk Kim, MD∗; Dong-Ho Shin, MD, MPH∗; Young-Guk Ko, MD∗; Donghoon Choi, MD∗; Yangsoo Jang, MD∗; Myeong-Ki Hong, MD∗

Objectives: This study sought to evaluate the relationship between post-stent strut apposition and follow-up strut coverage using contour plot optical coherence tomographic analysis.

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Erroneous Measurement of the Aortic Annular Diameter Using 2-Dimensional Echocardiography Resulting in Inappropriate CoreValve Size Selection

Darren Mylotte, MB, MD∗; Magdalena Dorfmeister, MD‡; Yacine Elhmidi, MD‡; Domenico Mazzitelli, MD‡; Sabine Bleiziffer, MD‡; Anke Wagner, MD‡; Timothee Noterdaeme, MD‡; Ruediger Lange, MD, PhD‡; Nicolo Piazza, MD, PhD∗

Objectives: This study sought to assess the differential adherence to transcatheter heart valve (THV)-oversizing principles between transesophageal echocardiography (TEE) and multislice computed tomography (CT) and its impact on the incidence of paravalvular leak (PVL).

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS. Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated With Decreased Hospitalizations

Brian R. Lindman, MD, MSCI∗; William J. Stewart, MD†; Philippe Pibarot, DVM, PhD‡; Rebecca T. Hahn, MD§; Catherine M. Otto, MD‖; Ke Xu, PhD¶; Richard B. Devereux, MD#; Neil J. Weissman, MD∗∗; Maurice Enriquez-Sarano, MD††; Wilson Y. Szeto, MD‡‡; Raj Makkar, MD§§; D. Craig Miller, MD‖‖; Stamatios Lerakis, MD¶¶; Samir Kapadia, MD†; Bruce Bowers, MD##; Kevin L. Greason, MD††; Thomas C. McAndrew, MS¶; Yang Lei, MS∗∗∗; Martin B. Leon, MD§; Pamela S. Douglas, MD†††

Objectives: This study sought to examine the relationship between left ventricular mass (LVM) regression and clinical outcomes after transcatheter aortic valve replacement (TAVR).

01 junio 2014

JACC: CARDIOVASCULAR INTERVENTIONS.Lumen Gain and Restoration of Pulsatility After Implantation of a Bioresorbable Vascular Scaffold in Porcine Coronary Arteries

Jennifer P. Lane, BS∗; Laura E.L. Perkins, DVM, PhD, DACVP∗; Alexander J. Sheehy, MS∗; Erica J. Pacheco, BS†; Michael P. Frie, BS‡; Byron J. Lambert, PhD∗; Richard J. Rapoza, PhD∗; Renu Virmani, MD†

Objectives: Using intravascular ultrasound (IVUS) and histomorphometry, this study sought to evaluate the potential of nonatherosclerotic porcine coronary arteries to undergo progressive lumen gain and a return of pulsatility after implantation with an everolimus-eluting bioresorbable vascular scaffold (BVS).

01 junio 2014

JACC. Caval-Aortic Access to Allow Transcatheter Aortic Valve Replacement in Otherwise Ineligible Patients

Adam B. Greenbaum, MD∗; William W. O´Neill, MD∗; Gaetano Paone, MD†; Mayra E. Guerrero, MD∗; Janet F. Wyman, DNP∗; R. Lebron Cooper, MD‡; Robert J. Lederman, MD§

Objectives: This study describes the first use of caval-aortic access and closure to enable transcatheter aortic valve replacement (TAVR) in patients who lacked other access options. Caval-aortic access refers to percutaneous entry into the abdominal aorta from the femoral vein through the adjoining inferior vena cava.

01 julio 2014

JACC. A Randomized Comparison of Platinum Chromium-Based Everolimus-Eluting Stents Versus Cobalt Chromium-Based Zotarolimus-Eluting Stents in All-Comers Receiving Percutaneous Coronary Intervention. HOST–ASSURE (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen), a Randomized, Controlled, Noninferiority Trial

Kyung Woo Park, MD, PhD∗; Si-Hyuck Kang, MD, MSc∗; Hyun-Jae Kang, MD, PhD∗; Bon-Kwon Koo, MD, PhD∗; Byoung-Eun Park, MD, PhD†; Kwang Soo Cha, MD, PhD‡; Jay Young Rhew, MD, PhD§; Hui-Kyoung Jeon, MD, PhD‖; Eun-Seok Shin, MD, PhD¶; Ju Hyeon Oh, MD, PhD#; Myung-Ho Jeong, MD, PhD∗∗; Sanghyun Kim, MD, PhD††; Kyung-Kuk Hwang, MD, PhD‡‡; Jung-Han Yoon, MD, PhD§§; Sung Yun Lee, MD, PhD‖‖; Tae-Ho Park, MD, PhD¶¶; Keon Woong Moon, MD, PhD##; Hyuck-Moon Kwon, MD, PhD∗∗∗; Seung-Ho Hur, MD, PhD†††; Jae-Kean Ryu, MD, PhD‡‡‡; Bong-Ryul Lee, MD, PhD§§§; Yong Whi Park, MD, PhD‖‖‖; In-Ho Chae, MD, PhD¶¶¶; Hyo-Soo Kim, MD, PhD∗

Objectives: This study sought to test whether the newly developed platinum chromium (PtCr)-based everolimus-eluting stent (EES) is noninferior to the cobalt chromium (CoCr)-based zotarolimus-eluting stent (ZES) in all-comers receiving percutaneous coronary intervention (PCI).

01 julio 2014

JACC. Implications of Coronary Artery Disease in Heart Failure With Preserved Ejection Fraction

Seok-Jae Hwang, MD, PhD∗; Vojtech Melenovsky, MD, PhD∗; Barry A. Borlaug, MD∗

Objectives: This study investigated the characteristics, evaluation, prognostic impact, and treatment of coronary artery disease (CAD) in patients with heart failure and preserved ejection fraction (HFpEF).

01 junio 2014

JACC. Causes of Early Stent Thrombosis in Patients Presenting With Acute Coronary Syndrome

Masataka Nakano, MD∗; Kazuyuki Yahagi, MD∗; Fumiyuki Otsuka, MD, PhD∗; Kenichi Sakakura, MD∗; Aloke V. Finn, MD†; Robert Kutys, MS∗; Elena Ladich, MD∗; David R. Fowler, MD‡; Michael Joner, MD∗; Renu Virmani, MD∗

Objectives: The study interrogated an autopsy registry to investigate the histopathologic features of early stent thrombosis (ST) in patients presenting with acute coronary syndrome (ACS).

01 junio 2014

JACC. Distinct Morphological Features of Ruptured Culprit Plaque for Acute Coronary Events Compared to Those With Silent Rupture and Thin-Cap Fibroatheroma

Jinwei Tian, MD, PhD∗; Xuefeng Ren, MD∗; Rocco Vergallo, MD†; Lei Xing, MD∗; Huai Yu, MD∗; Haibo Jia, MD, PhD∗; Tsunenari Soeda, MD, PhD†; Iris McNulty, RN†; Sining Hu, MD∗; Hang Lee, PhD‡; Bo Yu, MD, PhD∗; Ik-Kyung Jang, MD, PhD†

Objectives: The study sought to identify specific morphological characteristics of ruptured culprit plaques (RCP) responsible for acute events, and compare them with ruptured nonculprit plaques (RNCP) and nonruptured thin-cap fibroatheroma (TCFA) in patients presenting with acute coronary syndromes (ACS).